{"product_id":"slrx-vrio-analysis","title":"Salarius Pharmaceuticals, Inc. (SLRX): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Salarius Pharmaceuticals, Inc. (SLRX) truly positioned for sustained success? This VRIO analysis cuts straight to the core, dissecting the firm's resources and capabilities against the crucial tests of Value, Rarity, Inimitability, and Organization to determine its current competitive advantage - or lack thereof. Dive in below to uncover the strategic strengths and weaknesses that will define Salarius Pharmaceuticals, Inc. (SLRX)'s future market standing.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSalarius Pharmaceuticals, Inc. (SLRX) - VRIO Analysis: 1. IMP3ACT™ Peptide Conjugate Platform\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at the core engine of the newly combined entity following the November 13, 2025, merger with Decoy Therapeutics. This platform, IMP3ACT™, is the reason for the strategic shift, and its capabilities dictate the future valuation of the stock trading as SLRX. Honestly, the platform’s success hinges on its ability to consistently deliver clinical candidates faster than the old guard.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Allows for rapid computational design and manufacturing of novel peptide therapeutics, potentially speeding up the drug development timeline.\u003c\/h3\u003e\n\u003cp\u003eThe value proposition here is speed and breadth. The IMP3ACT™ platform uses Artificial Intelligence (AI) and Machine Learning (ML) alongside high-speed synthesis to create peptide conjugate therapeutics. This isn't just theory; we saw evidence of this efficiency when computational tools identified a measles antiviral binding in just \u003cstrong\u003e5 days\u003c\/strong\u003e. The combined company, now focused on advancing this pipeline, has a clear near-term goal: advancing the lead pan-coronavirus antiviral to an Investigational New Drug (IND) filing within \u003cstrong\u003e12 months\u003c\/strong\u003e of the November 2025 merger close. This speed is critical for addressing urgent needs, like the pipeline assets targeting flu, COVID-19, and Respiratory Syncytial Virus (RSV).\u003c\/p\u003e\n\u003cp\u003eHere’s a quick look at the immediate focus areas leveraging this value:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eLead pan-coronavirus antiviral IND filing target: \u003cstrong\u003eNovember 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOther pipeline focus: GI cancers and broad-acting antivirals.\u003c\/li\u003e\n\u003cli\u003eIntegration potential: Incorporating the former Salarius asset SP-3164 into a PROTACS candidate.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRarity: The specific combination of AI\/ML, high-speed synthesis, and peptide expertise within this platform is likely rare in the current biotech landscape.\u003c\/h3\u003e\n\u003cp\u003eRarity in biotech often comes down to proprietary technology that others can’t easily replicate or access. The specific integration of AI\/ML for peptide design with high-speed manufacturing is what sets IMP3ACT™ apart. While AI in drug discovery is growing, this particular, proven combination is scarce. Furthermore, the platform has already attracted significant external validation, securing non-dilutive funding totaling approximately \u003cstrong\u003e$7 million\u003c\/strong\u003e from sources including BARDA, the Google AI program, and NVIDIA Inception. That external belief in the platform’s uniqueness helps solidify its rare status.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: High, as the platform is proprietary and built on years of specific R\u0026amp;D, making direct replication difficult.\u003c\/h3\u003e\n\u003cp\u003eReplicating this platform isn't a matter of just licensing software; it requires deep, proprietary know-how built over years of specific research and development. The complexity lies in the algorithms trained on specific peptide data and the specialized synthesis capabilities. To directly imitate it, a competitor would need to replicate that institutional knowledge base, which is a time-consuming and expensive endeavor. Still, the platform’s success is contingent on continued innovation; if competitors catch up on the AI\/ML side, the advantage erodes.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: High, as the entire post-merger strategy is centered on leveraging this platform for multiple pipeline assets.\u003c\/h3\u003e\n\u003cp\u003eThe organization is clearly structured around this asset. The merger itself was a platform acquisition, shifting the entire strategic focus to IMP3ACT™. Leadership from Decoy, including CEO Frederick Pierce and CSO Barbara Hibner, now guides the combined entity, ensuring the platform remains central. The financial structure post-merger reflects this commitment: the company closed a public offering raising \u003cstrong\u003e$8 million\u003c\/strong\u003e on November 13, 2025, resulting in pro forma cash of approximately \u003cstrong\u003e$14 million\u003c\/strong\u003e, which is earmarked to advance these platform-derived assets. This alignment of capital, leadership, and corporate mandate signals high organizational capability to exploit the technology.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage: Sustained, provided the platform continues to generate clinically viable candidates faster than competitors.\u003c\/h3\u003e\n\u003cp\u003eThe potential for a sustained competitive advantage is real, but it’s conditional. The platform is currently a source of \u003cstrong\u003etemporary competitive advantage\u003c\/strong\u003e because the speed of clinical progression is the ultimate test. If the lead antiviral hits its IND target in November 2026 and shows strong initial human data, that advantage becomes much harder to erode. The combination of speed (rarity\/imitability) and corporate focus (organization) creates a strong foundation. The key metric to watch is the time-to-IND compared to industry benchmarks for similar targets.\u003c\/p\u003e\n\u003cp\u003eHere is a summary of the current state based on the November 2025 merger completion:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eSupporting Data\/Metric\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eIdentified measles antiviral binding in \u003cstrong\u003e5 days\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eSecured non-dilutive funding of approx. \u003cstrong\u003e$7 million\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eDifficult\u003c\/td\u003e\n\u003ctd\u003eProprietary AI\/ML and high-speed synthesis integration.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003ePro forma cash of \u003cstrong\u003e$14 million\u003c\/strong\u003e post-merger financing.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003ePotential Sustained\u003c\/td\u003e\n\u003ctd\u003eIND filing target for lead asset by \u003cstrong\u003eNovember 2026\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eIf onboarding takes 14+ days for the next preclinical milestone, churn risk rises for investor confidence in the platform’s speed claims.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSalarius Pharmaceuticals, Inc. (SLRX) - VRIO Analysis: 2. Pan-Coronavirus Antiviral Candidate\n\u003c\/h2\u003e\n\u003cp\u003eThe analysis below focuses on the Pan-Coronavirus Antiviral Candidate, leveraging post-merger data from the combination of Salarius Pharmaceuticals and Decoy Therapeutics, effective November 13, 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Addresses a massive, ongoing global health need, offering significant commercial upside if it reaches the market.\u003c\/p\u003e\n\u003cp\u003eThe asset targets respiratory infectious diseases, including flu, COVID-19, and respiratory syncytial virus (RSV). The combined entity reported pro forma cash of approximately \u003cstrong\u003e$14 million\u003c\/strong\u003e following the merger and a recent public offering, providing resources for development.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many firms are working on antivirals, but this one is advanced, with an IND filing expected within 12 months.\u003c\/p\u003e\n\u003cp\u003eThe development timeline is aggressive, targeting an Investigational New Drug (IND) application filing with the FDA within \u003cstrong\u003e12 months\u003c\/strong\u003e of the November 2025 merger closing.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low in the short term, as it is currently in the company’s exclusive development pipeline.\u003c\/p\u003e\n\u003cp\u003eThe candidate is a lead asset developed through the proprietary IMP3ACT™ platform.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High, with dedicated resources allocated post-merger to push this lead asset toward an IND filing.\u003c\/p\u003e\n\u003cp\u003eThe post-merger organization is led by Decoy founders, focusing on advancing the pipeline.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as success depends on clinical trial outcomes and patent strength against other emerging antivirals.\u003c\/p\u003e\n\n\u003cp\u003eKey Metrics and Development Focus:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric Category\u003c\/th\u003e\n\u003cth\u003eDetail\u003c\/th\u003e\n\u003cth\u003eAssociated Figure\/Timeline\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Position (Post-Merger)\u003c\/td\u003e\n\u003ctd\u003ePro Forma Cash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancing Activity (Nov 2025)\u003c\/td\u003e\n\u003ctd\u003eGross Proceeds from Underwritten Public Offering\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevelopment Timeline\u003c\/td\u003e\n\u003ctd\u003eTarget for IND Filing for Pan-Coronavirus Antiviral\u003c\/td\u003e\n\u003ctd\u003eWithin \u003cstrong\u003e12 months\u003c\/strong\u003e of November 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform Technology\u003c\/td\u003e\n\u003ctd\u003eMethod of Development\u003c\/td\u003e\n\u003ctd\u003eIMP3ACT™ platform using AI\/ML and high-speed synthesis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline Scope\u003c\/td\u003e\n\u003ctd\u003eAntiviral Targets\u003c\/td\u003e\n\u003ctd\u003ePan-coronavirus, Flu, COVID-19, and RSV\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eResource Allocation and Structure:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eManagement structure led by Decoy founders following the November 13, 2025 merger.\u003c\/li\u003e\n\u003cli\u003ePrior non-dilutive funding received from BARDA and the Google AI program.\u003c\/li\u003e\n\u003cli\u003eThe combined company reported approximately \u003cstrong\u003e5.9 million\u003c\/strong\u003e shares of common stock outstanding as of November 12, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSalarius Pharmaceuticals, Inc. (SLRX) - VRIO Analysis: 3. Seclidemstat (SP-2577) Clinical Data\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides human clinical data (Phase 1\/2) for an epigenetic inhibitor (LSD1 inhibitor), a proven mechanism in oncology. Seclidemstat ($\\text{SP-2577}$) is an oral, first-in-class, small molecule with reversible, noncompetitive inhibition of LSD1 ($\\text{IC}_{50}$: \u003cstrong\u003e25–50 nM\u003c\/strong\u003e).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; Phase 1\/2 data is valuable, but the specific data set for this molecule in its target indications is unique to the company. In an ongoing Phase 1 trial investigating single agent seclidemstat in advanced solid tumors ($\\text{NCT03895684}$), 3 pts with metastatic FET-translocated sarcomas had a median progression-free survival of 5.7 months (range: 4.3–7.2) with a best response of stable disease despite having a median of 5 (range: 1–7) prior therapies.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low, as the data is historical and owned by the company, though competitors can run similar trials. The molecule inhibits LSD1's enzymatic activity and scaffolding functions.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate; the focus has shifted to the Decoy pipeline, but this data still informs the combined entity’s epigenetic knowledge base. As of December 31, 2023, cash and cash equivalents were $5.9 million. Net loss for 2023 was $12.5 million, or $3.84 per share. Research and development expenses for 2023 were $7.2 million. The company has 2 employees. Current cash was expected to fund planned operations into the first half of 2025. The company announced a definitive agreement to merge with Decoy Therapeutics Inc..\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as the value erodes if later-stage trials fail or if newer, more effective LSD1 inhibitors emerge. The Phase 1\/2 study ($\\text{NCT04734990}$) in MDS and CMML in combination with azacitidine showed an objective response in 43% ($\\text{n} = \\mathbf{6\/14}$) of evaluable patients.\u003c\/p\u003e\n\u003cp\u003eKey clinical data points for Seclidemstat ($\\text{SP-2577}$):\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial\/Study\u003c\/td\u003e\n\u003ctd\u003eIndication\u003c\/td\u003e\n\u003ctd\u003eDosing\/Regimen\u003c\/td\u003e\n\u003ctd\u003e$\\text{N}$ (Evaluable)\u003c\/td\u003e\n\u003ctd\u003eObjective Response Rate (ORR)\u003c\/td\u003e\n\u003ctd\u003eMedian OS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 1 ($\\text{NCT03895684}$)\u003c\/td\u003e\n\u003ctd\u003eAdvanced Solid Tumors (FET-translocated sarcomas)\u003c\/td\u003e\n\u003ctd\u003eSingle Agent\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$\\text{N\/A}$ (Best response: Stable Disease)\u003c\/td\u003e\n\u003ctd\u003e$\\text{N\/A}$\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 1\/2 ($\\text{NCT04734990}$)\u003c\/td\u003e\n\u003ctd\u003eHigh-risk MDS\/CMML + Azacitidine\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e750\u003c\/strong\u003e mg twice daily (Dose escalation)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e14\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e43%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e18.5 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe $\\text{Phase 1\/2}$ study included specific response rates:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eComplete response in 1 patient.\u003c\/li\u003e\n\u003cli\u003eMarrow complete responses in 3 patients.\u003c\/li\u003e\n\u003cli\u003eComplete responses plus hematological improvement in 1 patient.\u003c\/li\u003e\n\u003cli\u003eHematological improvement in 1 patient.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSalarius Pharmaceuticals, Inc. (SLRX) - VRIO Analysis: 4. Pro Forma Cash Position\n\u003c\/h2\u003e\n\u003cp\u003e\nThe assessment of Pro Forma Cash Position focuses on the liquidity available to fund ongoing operations and research and development initiatives.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eValue:\u003c\/strong\u003e The cash position is supported by recent capital market activity, including a $7 million underwritten public offering announced in November 2025. Prior to this, gross proceeds of approximately $3.8 million were secured through the issuance of approximately 5.5 million shares pursuant to an equity line of credit in July 2025. The estimated cash and cash equivalents as of July 30, 2025, was approximately $4.5 million.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; cash resources are inherently fungible. However, the ability to secure financing, such as the $7 million offering, provides a specific operational runway that may be rare for a company with recent operating losses. The cash and cash equivalents as of December 31, 2024, were $2.4 million.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eImitability:\u003c\/strong\u003e Not applicable; this is a financial resource, not an inimitable organizational capability or asset.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the execution of the November 2025 $7 million offering and the July 2025 $3.8 million capital raise demonstrates the organization’s established ability to access capital markets to secure necessary liquidity.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; this liquidity buffer is essential for near-term operational continuity but is subject to rapid depletion due to operating expenses. The net loss for the third quarter ended June 30, 2025, was reported as approximately $874,000, or an expected loss of approximately $900,000 for that period.\n\u003c\/p\u003e\n\n\u003cp\u003e\nSelected Financial Metrics Related to Cash Position and Operations:\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount\/Date\u003c\/th\u003e\n\u003cth\u003eReference Period\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of December 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents (Estimated)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of July 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Proceeds from Equity Line\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJuly 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNovember 2025 Public Offering Size\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAnnounced November 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$874,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 (Three months ended June 30, 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss for 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear ended December 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\nDetails on Recent Financing and Cash Burn:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash and cash equivalents as of December 31, 2023, were \u003cstrong\u003e$5.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet cash used in operating activities for 2023 was \u003cstrong\u003e$12.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe November 2025 offering price was \u003cstrong\u003e$1.50\u003c\/strong\u003e per share of common stock with accompanying warrants.\u003c\/li\u003e\n\u003cli\u003eThe July 2025 financing involved issuing approximately \u003cstrong\u003e5.5 million shares\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe organization's net loss for the fourth quarter of 2023 was \u003cstrong\u003e$0.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSalarius Pharmaceuticals, Inc. (SLRX) - VRIO Analysis: 5. Nasdaq Listing Compliance\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Maintaining a listing on the Nasdaq Capital Market ensures access to public capital markets, evidenced by a recent underwritten public offering aiming to raise gross proceeds of \u003cstrong\u003e$7 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; compliance is a regulatory requirement, though regaining compliance after receiving notices for non-compliance under specific rules is an organizational feat. The company regained compliance with Nasdaq Listing Rule 5550(a)(2) (Minimum Bid Price Rule) on September 4, 2025, and with Nasdaq Listing Rule 5550(b)(1) (Equity Standard) on October 10, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Not applicable; it is a status that competitors either have or must achieve.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the company successfully navigated delisting threats, showing organizational focus on maintaining public status following notices of non-compliance.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e None; it is a baseline requirement for operating as a listed entity.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eNasdaq Listing Rule\u003c\/th\u003e\n\u003cth\u003eRequirement Threshold\u003c\/th\u003e\n\u003cth\u003eDate of Non-Compliance Notice\u003c\/th\u003e\n\u003cth\u003eDate of Compliance Confirmation\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e5550(a)(2) - Minimum Bid Price\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$1.00\u003c\/strong\u003e per share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eApril 23, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSeptember 4, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e5550(b)(1) - Equity Standard\u003c\/td\u003e\n\u003ctd\u003eMinimum stockholders' equity of \u003cstrong\u003e$2.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMarch 26, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eOctober 10, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe company is subject to a Mandatory Panel Monitor for a period of \u003cstrong\u003eone year\u003c\/strong\u003e from \u003cstrong\u003eOctober 10, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Form 10-K for the fiscal year ended \u003cstrong\u003eDecember 31, 2024\u003c\/strong\u003e, triggered the Equity Standard non-compliance notice.\u003c\/li\u003e\n\u003cli\u003eThe company's market capitalization was reported as \u003cstrong\u003e$0.97 million\u003c\/strong\u003e with shares trading at \u003cstrong\u003e$0.93\u003c\/strong\u003e as of November 17, 2025.\u003c\/li\u003e\n\u003cli\u003eThe net loss for the three months ended September 30, 2025, was \u003cstrong\u003e$873,467\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe net loss for the nine months ended September 30, 2025, was \u003cstrong\u003e$3,540,825\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eExecutive stock options include grants for \u003cstrong\u003e5,061\u003c\/strong\u003e shares at an exercise price of \u003cstrong\u003e$4.9369\u003c\/strong\u003e per share.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSalarius Pharmaceuticals, Inc. (SLRX) - VRIO Analysis: 6. Peptide Conjugate Drug Development Expertise\n\u003c\/h2\u003e\n\u003cp\u003eThe analysis focuses on the expertise in peptide conjugate drug development, primarily derived from the integration of Decoy Therapeutics' IMP3ACT™ platform following the merger.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Deep, specialized scientific knowledge in designing and engineering peptide conjugate therapeutics, a complex area of drug modality.\u003c\/p\u003e\n\u003cp\u003eThe expertise is underpinned by the IMP3ACT™ platform, which leverages Artificial Intelligence (AI) and Machine Learning (ML) tools alongside high-speed synthesis techniques. \u003cstrong\u003e$7 million\u003c\/strong\u003e in non-dilutive funding was secured by Decoy from entities including The Bill \u0026amp; Melinda Gates Foundation for this technology.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2023 Amount\u003c\/th\u003e\n\u003cth\u003e2024 Amount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.77 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; this specialized skill set, especially when combined with the IMP3ACT™ platform, is scarce.\u003c\/p\u003e\n\u003cp\u003eThe platform's ability to rapidly design, engineer, and manufacture peptide conjugate drug candidates contributes to its scarcity.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; it requires years of specialized training and tacit knowledge within the R\u0026amp;D team.\u003c\/p\u003e\n\u003cp\u003eThe historical R\u0026amp;D investment by Salarius, prior to the merger, reflects the sustained financial commitment required in this scientific domain. The combined entity's pro forma cash position post-merger was \u003cstrong\u003e$14 million\u003c\/strong\u003e as of November 13, 2025.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePrior SLRX R\u0026amp;D Expense (2023): \u003cstrong\u003e$7.2 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003ePrior SLRX R\u0026amp;D Expense (2022): \u003cstrong\u003e$15.8 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; this is the primary strategic focus of the newly merged entity.\u003c\/p\u003e\n\u003cp\u003eThe combined company is now named Decoy Therapeutics, with Decoy shareholders retaining approximately \u003cstrong\u003e86%\u003c\/strong\u003e ownership. The immediate focus includes advancing the lead asset, a pan-coronavirus antiviral, to an Investigational New Drug (IND) application filing within the next \u003cstrong\u003e12 months\u003c\/strong\u003e (from early 2025).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as this core scientific competency is difficult for generalist biotechs to replicate quickly.\u003c\/p\u003e\n\u003cp\u003eThe platform aims to advance new therapies from lab to clinic to commercialization with unprecedented speed. The company completed an underwritten public offering raising gross proceeds of \u003cstrong\u003e$8 million\u003c\/strong\u003e on November 13, 2025.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSalarius Pharmaceuticals, Inc. (SLRX) - VRIO Analysis: 7. Focus on Epigenetic \u0026amp; Post-Translational Modification Pathways\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Concentrates R\u0026amp;D efforts on key regulatory mechanisms in cancer, positioning the company in a high-potential precision medicine area.\u003c\/p\u003e\n\u003cp\u003eThe focus on Lysine Specific Demethylase 1 (LSD1) inhibition via Seclidemstat (SP-2577) targets a well-validated mechanism in hematologic and solid tumors, with preclinical data showing reduced tumor burden and prolonged survival in models. The company's pipeline also includes SP-3164, a targeted protein degrader.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSP-2577 is being studied in a Phase 1\/2 trial for Ewing sarcoma and in an investigator-initiated Phase 1\/2 trial at MD Anderson Cancer Center (MDACC) for myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) in combination with azacitidine.\u003c\/li\u003e\n\u003cli\u003eInterim clinical trial results from the MDACC study reported a \u003cstrong\u003e43% overall response rate\u003c\/strong\u003e among 14 predominantly higher-risk MDS and CMML patients who previously failed hypomethylating agent therapy.\u003c\/li\u003e\n\u003cli\u003eMedian overall survival in that patient group was reported as \u003cstrong\u003e18.5 months\u003c\/strong\u003e, compared to a typical survival of four to six months after failing hypomethylating agents.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many biotechs target epigenetics, but the specific focus on NEDD8-activating enzymes and LSD1 is more niche.\u003c\/p\u003e\n\u003cp\u003eWhile epigenetics is a broad area, the specific development of SP-2577, an orally bioavailable LSD1 inhibitor that inhibits both enzymatic and scaffolding functions, provides a degree of differentiation.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eTarget\/Mechanism\u003c\/th\u003e\n\u003cth\u003eClinical Status\u003c\/th\u003e\n\u003cth\u003eEstimated Market Potential\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSeclidemstat (SP-2577)\u003c\/td\u003e\n\u003ctd\u003eLSD1 Inhibitor (Enzymatic \u0026amp; Scaffolding)\u003c\/td\u003e\n\u003ctd\u003ePhase 1\/2 (Ewing Sarcoma, MDS\/CMML)\u003c\/td\u003e\n\u003ctd\u003eInitial ES market ~$\u003cstrong\u003e200 million\u003c\/strong\u003e; potential to expand to ~$\u003cstrong\u003e1B\u003c\/strong\u003e or more.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSP-3164\u003c\/td\u003e\n\u003ctd\u003eTargeted Protein Degrader (Molecular Glue)\u003c\/td\u003e\n\u003ctd\u003eIND-enabling studies (planned clinical trial H2 2023, now incorporated post-merger)\u003c\/td\u003e\n\u003ctd\u003eIncorporated into a highly targeted peptide-based PROTAC drug candidate.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; competitors can pivot to this area, but the company has historical institutional knowledge here.\u003c\/p\u003e\n\u003cp\u003eThe technology for SP-2577 was licensed from the University of Utah Huntsman Cancer Institute, representing established institutional knowledge in this specific LSD1 inhibition approach.\u003c\/p\u003e\n\u003cp\u003eFinancial commitment to this focus area, despite recent shifts, is evidenced by R\u0026amp;D spending:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eR\u0026amp;D Expenses for SP-3164 in Q3 2025 were \u003cstrong\u003e$41,057\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D Expenses for SP-2577 in Q3 2025 were \u003cstrong\u003e$20,769\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; this was the original Salarius focus and remains a key part of the combined pipeline.\u003c\/p\u003e\n\u003cp\u003eDespite the merger with Decoy Therapeutics, the LSD1 inhibitor and protein degrader programs remain explicitly part of the combined entity's plans. The company reported only \u003cstrong\u003e2\u003c\/strong\u003e employees as of March 31, 2025.\u003c\/p\u003e\n\u003cp\u003eLiquidity metrics as of September 30, 2025:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash and Cash Equivalents: \u003cstrong\u003e$4.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eProjected cash runway through \u003cstrong\u003eQ1 2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQuarterly Net Loss (Q3 2025): \u003cstrong\u003e$0.87 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as scientific focus areas can shift, but it provides a clear research direction now.\u003c\/p\u003e\n\u003cp\u003eThe differentiated mechanism of SP-2577, inhibiting both enzymatic and scaffolding functions, offers a potential advantage over irreversible LSD1 inhibitors that have shown hematologic toxicity. The company's net loss for the nine months ended September 30, 2025, was \u003cstrong\u003e$3.54 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSalarius Pharmaceuticals, Inc. (SLRX) - VRIO Analysis: 8. Collaboration with Texas Biomedical Research Institute\u003c\/h2\u003e\n\n\u003cp\u003e\nThe collaboration with Texas Biomedical Research Institute (TBRI) is assessed below based on the VRIO framework.\n\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Attribute\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eAccess to external research capabilities; testing of peptide conjugate fusion inhibitors against influenza strains including \u003cstrong\u003eH5N1 avian flu\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003e\nThe collaboration provides access to TBRI's leading \u003cem\u003ein vitro\u003c\/em\u003e virology testing capabilities for Decoy Therapeutics' peptide conjugate fusion inhibitors, which utilize the IMP3ACT™ platform.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTesting scope includes several influenza strains, specifically noting \u003cstrong\u003eH5N1 avian flu\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe inhibitors show excellent \u003cem\u003ein silico\u003c\/em\u003e free energy binding to the viral target entry protein.\u003c\/li\u003e\n\u003cli\u003eThe collaboration was announced on \u003cstrong\u003eDecember 1, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003e\nThe Rarity assessment is low, as academic and research collaborations are common in the biopharmaceutical sector.\n\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003e\nThe Imitability assessment is low; other entities can form similar partnerships.\n\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003e\nThe organization aspect is moderate, evidenced by securing external validation for pipeline assets. Financial context surrounding this development includes:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGross proceeds raised from an underwritten public offering on \u003cstrong\u003eNovember 13, 2025\u003c\/strong\u003e: \u003cstrong\u003e$8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ2 2025 operating expenses (opex) were \u003cstrong\u003e$0.97M\u003c\/strong\u003e, down from \u003cstrong\u003e$1.47M\u003c\/strong\u003e in Q2 2024.\u003c\/li\u003e\n\u003cli\u003eQ2 2025 net loss was \u003cstrong\u003e$0.96M\u003c\/strong\u003e with diluted EPS of \u003cstrong\u003e$(0.45)\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash position rose to \u003cstrong\u003e~$4.5M\u003c\/strong\u003e by \u003cstrong\u003eJuly 30\u003c\/strong\u003e after equity line drawdowns.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003e\nThe advantage is temporary, contingent on tangible, positive results from the collaboration. Financial metrics as of recent reports include:\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrailing 12 Months Earnings (ending Sep 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$5.0M\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares Outstanding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5.86 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Cap\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.84 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e52-Week Price Change\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-96.21%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLast Stock Split Ratio (Aug 18, 2025)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1:15\u003c\/strong\u003e (Reverse)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eSalarius Pharmaceuticals, Inc. (SLRX) - VRIO Analysis: 9. Experience in Oncology Drug Development and Regulatory Strategy\n\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThe management team's background supports navigating the complex clinical trial design and FDA submission processes for cancer drugs. CEO David J. Arthur possesses \u003cstrong\u003emore than 35 years\u003c\/strong\u003e of US and global pharmaceutical experience, integrating strategy, pricing, development, and clinical planning into lifecycle plans. \u003cstrong\u003eDr. Mirza\u003c\/strong\u003e conducted clinical research at MD Anderson Cancer Center from \u003cstrong\u003e1992 - 2004\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eModerate; experienced teams are common in established pharma, but less so in smaller clinical-stage biotechs.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eLow; key personnel are not easily replaced or replicated.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eHigh; this experience is crucial for executing the planned IND filings and future commercialization strategy. The company has its second asset, SP-3164, at the \u003cstrong\u003eIND-stage\u003c\/strong\u003e. The lead candidate, seclidemstat (SP-2577), is being studied in an investigator-initiated \u003cstrong\u003ePhase 1\/2\u003c\/strong\u003e clinical study at MD Anderson Cancer Center (MDACC) for hematologic cancers. Seclidemstat has received \u003cstrong\u003eOrphan Drug Designation\u003c\/strong\u003e and \u003cstrong\u003eRare Pediatric Disease Designation\u003c\/strong\u003e for Ewing sarcoma from the U.S. Food and Drug Administration (FDA).\u003c\/p\u003e\n\n\u003cp\u003eThe operational capacity is supported by external funding and clinical results:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSalarius was a recipient of a three-year \u003cstrong\u003e$16.1 million\u003c\/strong\u003e Cancer Prevention and Research Institute of Texas (CPRIT) New Company Product Development award.\u003c\/li\u003e\n\u003cli\u003eInterim data from the MDACC investigator-initiated trial of seclidemstat in combination with azacitidine reported a \u003cstrong\u003e43% overall response rate\u003c\/strong\u003e out of \u003cstrong\u003e14 evaluable patients\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThis response rate compares to a typical overall survival of \u003cstrong\u003efour to six months\u003c\/strong\u003e after failing therapy with hypomethylating agents, whereas the trial reported a median overall survival of \u003cstrong\u003e18.5 months\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eKey financial metrics reflecting resource management and operational scale:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue (FY 2024 or Dec 31, 2024)\u003c\/td\u003e\n\u003ctd\u003eValue (TTM or Prior Period)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss (Per Share)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.79\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$30.74 (Net Loss Per Share for 2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss (Total)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$12.5 million (Net Loss for 2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$2.4 million\u003c\/strong\u003e (as of Dec 31, 2024)\u003c\/td\u003e\n\u003ctd\u003e$5.9 million (as of Dec 31, 2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEBITDA (Thousands USD)\u003c\/td\u003e\n\u003ctd\u003e(303) (FY 2024)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e($5,064)\u003c\/strong\u003e (TTM)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eKey personnel are not easily replaced or replicated.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eHigh; this experience is crucial for executing the planned IND filings and future commercialization strategy.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained, as institutional experience reduces execution risk, which is a major factor in biotech valuation.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516252479637,"sku":"slrx-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/slrx-vrio-analysis.png?v=1740212751","url":"https:\/\/dcf-model.com\/fr\/products\/slrx-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}